Abstract 1434P
Background
FRUTIGA study showed OS improvement but was not statistically significant in the ITT population who had advanced G/GEJ adenocarcinoma receiving F plus PTX over placebo plus PTX (mOS: 9.67 vs 8.41 mo, HR=0.96, p=0.6064; Xu RH, et al, 2024 ASCO #438780). Here we explored the effect of subsequent anti-tumor therapies on OS in this study.
Methods
A post-hoc analysis for the effect of subsequent anti-tumor therapies on OS (randomization to death from any cause) using Kaplan-Meier method was conducted.
Results
A total of 439/703 pts (F+PTX vs placebo + PTX: 185/351 [52.7%] vs 254/352 [72.2%]) received subsequent anti-tumor therapies. There were 33.7% (28.2% vs 39.2%), 16.9% (14.2% vs 19.6%), and 9.1% (7.4% vs 10.8%) of pts received 1, 2 or ≥ 3 subsequent anti-tumor regimens, respectively. Apatinib (23.1% vs 35.2%), irinotecan (20.8% vs 27.8%) and anti PD-1/PD-L1 antibodies (20.8% vs 27.6%) were the most common subsequent regimens; few pts (3.4% vs 5.7%) used anti-HER2/Claudin 18.2 regimens. Detailed results of impact of subsequent anti-tumor therapies on OS are shown in the table below. Table: 1434P
| F+PTX (N = 351) n (%) | PTX (N = 352) n (%) | Median OS, mo (F+PTX vs PTX) | HR | |
| Subsequent treatment | 185 (52.7) | 254 (72.2) | 12.22 vs 9.95 | 0.91 (0.73, 1.12) |
| Apatinib | 81 (23.1) | 124 (35.2) | 13.01 vs 10.81 | 0.95 (0.70, 1.30) |
| Irinotecan | 73 (20.8) | 98 (27.8) | 12.22 vs 10.71 | 0.92 (0.67, 1.27) |
| Anti PD-1/PD-L1 – ICI naïve# | 68 (19.4) | 86 (24.4) | 13.90 vs 13.60 | 1.12 (0.77, 1.62) |
| Anti PD-1/PD-L1 – ICI pre-treated∗ | 5 (1.4) | 11 (3.1) | 14.52 vs 14.75 | 0.73 (0.18, 2.94) |
| Anti HER2/Claudin 18.2& | 12 (3.4) | 20 (5.7) | 13.77 vs 16.10 | 2.09 (0.82, 5.30) |
∗Pts who had received prior anti PD-1/PD-L1 antibodies treatment.#Pts who had not received prior anti PD-1/PD-L1 antibodies treatment.&Pts who had not received prior HER2.
Conclusions
Pts who received 3L standard regimens (apatinib, irinotecan) for the subsequent anti-tumor therapies had the consistent OS improvement as shown in ITT population. Subsequent anti PD-1/PD-L1 therapies for pts who had received previous anti PD-1/PD-L1 antibodies could have no potential impact on OS benefit in FRUTIGA study.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
P. Tan, W. Su: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16
596P - Dose-individualisation of fluoropyrimidines in <italic>DPYD</italic> wild-type patients: Final results from the Alpe2U study
Presenter: Niels Heersche
Session: Poster session 16